Dysregulated alternative splicing in DM1 hiNeurons at 10 DPI. by Mougina K. Eltahir (12988153)

“…(d) Scatter plots pertaining to Fig 5c show decreased inclusion of <i>MAPT</i> e2 (top), <i>CSNK1D</i> e9 (bottom left) and <i>MPRIP</i> e9 (bottom right) in DM1 hiNeurons. …”

A deficiency of TLR9 decreases chronic stress-induced changes of pro-inflammatory cytokine levels by macrophages TLR9 knockout mice or wild type BALB/c mice aged 6 to 8 weeks were... by Yanxiao Xiang (468904)

Phenotypic characterization of <i>CsIVP</i>-RNAi transgenic plants. by Shuangshuang Yan (798064)

“…<p>(A) Plant morphology of WT and <i>CsIVP-</i>RNAi lines R5, R3, and R2. …”

Mendelian randomization results with COVID-19. by Alish B. Palmos (5857379)

Schematic diagram of STTFP model. by Guozhu Sui (21672798)

Effect of obesity on contraction of mesenteric arteries to angiotensin II and norepinephrine. by Graziela N. Hagihara (623403)

Contribution of angiotensin II receptors activation to the vascular effects of angiotensin. by Graziela N. Hagihara (623403)

Effect of angiotensin II on eNOS phosphorylation in mesenteric arteries. by Graziela N. Hagihara (623403)

PCAIs inhibit NCI-H23 cell line viability. by Matthew D. Gregory (19929096)

“…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”

PCAIs disrupt actin filaments in NCI-H23 cells. by Matthew D. Gregory (19929096)

“…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”

PCAIs suppress 3D NCI-H23 cell invasion. by Matthew D. Gregory (19929096)

“…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”

PCAIs suppress NCI-H23 cancer cell migration. by Matthew D. Gregory (19929096)

“…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”

PCAIs induce apoptosis in NCI-H23 cells. by Matthew D. Gregory (19929096)

“…Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of potential cancer therapy agents that we designed to specifically disrupt and suppress hyperactive G-protein signaling, such as that caused by mutated RAS proteins. …”

Expression of CRYAB in normal and tumor tissue samples across different cancer types. by Rasool Saghaleyni (10526301)

DNMT1 reduces cisplatin sensitivity partially through downregulating FOXO3a in ovarian cancer cells by Chong Guo (5819105)

“…Knocking down of DNMT1 could decrease the IC₅₀ of cisplatin. Treatment with cisplatin may reduce FOXO3a expression in OC cells. …”

The number of days until tumor confirmation is inversely proportional to the amount of inoculated F98 cells in the five rat groups. by Velislava Zoteva (17720500)

Flow cytometer analysis of the different cell populations in the absence or presence of 1 μg/ml doxycycline for 5 days. by Nicolas Jullien (82773)

Hopping into a hot seat: Role of DNA structural features on IS<i>5</i>-mediated gene activation and inactivation under stress - Fig 7 by M. Zafri Humayun (4217524)

“…The G(x) values are decreased for the <i>ORF-3</i> mutation (blue), meaning that the duplex is further destabilized relative to the wild type sequence. …”

Effects of angiotensin II on ERK 1/2 phosphorylation in mesenteric arteries. by Graziela N. Hagihara (623403)

Efficiency of explaining and predicting risk premium in different samples. by Mihály Ormos (697939)